Jump to content

CST - CASTILE RESOURCES LTD


colaiscute

Recommended Posts

Am I the only bunny that didn't sell on market.

 

Held out for a few extra cents while the overal market weakness of the last few weeks has thown up a few nice oppertunities.

 

Hope I havent missed the boat again.

 

 

Where can I get a nice hot coffee at Sharescene, the ones here have gone cold!

 

 

RIP CST

 

 

 

 

post-3516-1313544727_thumb.jpg

Link to comment
Share on other sites

  • Replies 22k
  • Created
  • Last Reply

Top Posters In This Topic

  • forrestgump

    1573

  • rog

    1833

  • dr_dazmo

    1257

  • skorpian

    1585

Top Posters In This Topic

Posted Images

Hi Big T

 

I think you'll find there'll be a few boats leaving in the coming months / years, so missing one won't make much difference. I also have waited to squeeze the last cents out of the deal.

 

Will very much miss the high quality posts that have characterised the CST thread over the past years.

 

Best of luck to all the long time CST holders, and I hope another great stock comes along for you.

 

Cheers

J

Link to comment
Share on other sites

Qiagen buys out CST and now PFE partners up with it. Should've been the other way around. Am sure PFE wouldn't have made this move if CST wasn't in the bag.

 

Recently, Qiagen (NasdaqGS: QGEN - News) entered into an agreement with Pfizer Inc. (NYSE: PFE - News) to develop a companion molecular diagnostic test for use with an investigational Pfizer compound for treating non-small cell lung cancer (NSCLC). Financial terms of the deal were not disclosed. The proposed test will use the same core assay component as QiagenÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s proprietary KRAS assay technology, which detects mutations of the KRAS gene, frequently found in human colorectal cancers.

 

Earlier this month, Qiagen opted for the pre-market approval from US Food and Drug Administration (FDA) for KRAS companion diagnostics for use with two other separate drugs targeting metastatic colorectal cancers. Through this partnership, Qiagen expects to develop the KRAS companion diagnostic for use with dacomitinib (PF-00299804). This partnership will also cover clinical trials and submissions for a pre-market approval application in the US and the CE mark in Europe, as well as approvals in other regions.

 

Companion diagnostics are currently gaining significant traction and peers of Qiagen like Myriad Genetics (MYGN</SPAN>'>MYGN) are establishing themselves as strong players in the companion diagnostics market. However, this latest move on QiagenÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s part is e xpected to strengthen its foothold in this market by combining its excellence in companion diagnostics with Pfizer's scientific and global background while developing innovative diagnostic-therapeutic care with the potential to improve the treatment of NSCLC patients.

 

The molecular diagnostics segment of Qiagen contributed to 46% of total sales in the second quarter of fiscal 2011 and registered a 2% growth at constant exchange rate (CER) on the back of solid growth in consumable products, partially offset by lower instrument sales. However, the comparison was hampered by higher one-time contributions in the prior-year quarter, which included payments for companion diagnostic co-development projects to pharmaceutical companies.

 

Going forward, the company expects a wave of newly discovered biomarkers and companion diagnostics to transform the treatment of a number of diseases.

Link to comment
Share on other sites

PFE is a giant with a market cap of over $144 billion.

 

What makes you so sure that CST plays such a big part in their corporate plans as to persuade them into this new partnership? That would seem a pretty oblique way to go about things when they could have had CST for themselves once it was in play!

Link to comment
Share on other sites

Oblique it is but surely you don't expect PFE to trumpet their end game strategy from the roof tops do you? If you want a good example of PFE and oblique look no further than their treatment or lack of towards BLT while at the same time they are working hand in glove handing over the money to Tacere. A company set up by BLT's previous management using BLT technology.

 

And Macduffy, haven't you heard? Size doesn't matter!

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...